Efficacy and safety of adding LX4211 (an investigational oral compound) for patients with Type 1 Diabetes Mellitus (T1D) who have inadequate control of their blood glucose (sugar) levels on insulin alone The primary objective of this study is to demonstrate superiority of either LX4211 400 mg or 200 mg versus placebo on glycosylated hemoglobin A1C (A1C) reduction at Week 24 when used as an adjunct in ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects with Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy The primary objectives of this study are: • To evaluate the safety and tolerability of three dose levels of LX3305 over 12 weeks in subjects with active RA who are also receiving stable doses of MTX; ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to examine the advantage of Sotagliflozin in addition to Insulin therapy in patients with Type 1 Diabetes Studie zkoumající výhody sotagliflozinu jako doplňku inzulinové léčby pacientů s diabetem I. typu To demonstrate the superiority of sotagliflozin 400 mg versus placebo in the proportion of patients with glycosylated A1C <7.0% at Week 24 and no episode of severe hypoglycemia and no episode of diabe...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606) The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects with Symptomatic Carcinoid Syndrome The primary objective of this study is to evaluate the safety and tolerability of orally administered LX1606 in subjects with symptomatic carcinoid syndrome.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Estudio en fase 3, aleatorizado, multicéntrico, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de etiprato de telotristat (LX1606) en pacientes con síndrome carcinoide To evaluate the effect of telotristat etiprate versus placebo over the double-blind portion of the study on the incidence of treatment-emergent adverse events (TEAEs) Evaluar el efecto del etipr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Research Study of the Efficacy and Safety of Telotristat Etiprate for Carcinoid Syndrome Patients, Who Do Not Respond to Somatostatin Analogue Therapy Studio Clinico per valutare l'efficacia e la sicureza di telotristat etiprato per i pazienti con sindrome da carcinoide (SC) che non rispondono alla terapia con analoghi della somatostatina The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the change from baseline in the number of daily bo...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Pilot Study to Evaluate Safety and Efficacy of LX1606 in Subjects With Acute, Mild to Moderate Ulcerative Colitis The primary objective of this study is to evaluate the safety and tolerability of orally administered LX1606 after 8 weeks in a cohort of subjects with acute, mild to moderate ulcerative colitis.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune